Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
Expiration | Code | ||
---|---|---|---|
VORTIOXETINE HYDROBROMIDE, TRINTELLIX, TAKEDA PHARMS USA | |||
2024-01-22 | M-187 | ||
2023-11-13 | M-267 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Vortioxetine Hydrobromide, Trintellix, Takeda Pharms Usa | |||
9278096 | 2032-03-21 | U-2436 | |
8722684 | 2031-06-30 | DS, DP | |
8969355 | 2027-06-15 | U-1668 | |
9125908 | 2027-06-15 | U-2309 | |
9125909 | 2027-06-15 | U-2309 | |
9125910 | 2027-06-15 | U-2309 | |
9227946 | 2027-06-15 | U-1668 | |
9861630 | 2027-06-15 | U-1668 | |
11458134 | 2027-06-15 | DP | U-3463 |
7144884 | 2026-06-17 | DS, DP | U-1439 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 4 | 9 | 31 | 13 | 8 | 63 |
Depression | D003863 | — | F33.9 | 2 | 2 | 2 | 5 | — | 9 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 2 | 6 | 1 | — | 8 |
Healthy volunteers/patients | — | — | — | 4 | — | — | 1 | — | 5 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | 2 | — | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 2 | — | 2 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | 1 | — | 2 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | 1 | 2 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | — | 1 | — | 1 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Treatment outcome | D016896 | — | — | — | — | 1 | — | — | 1 |
Radiation injuries | D011832 | — | T66 | — | — | 1 | — | — | 1 |
Hoarding disorder | D000067836 | — | F42.3 | — | — | 1 | — | — | 1 |
Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
Burning mouth syndrome | D002054 | EFO_1000850 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Binge-eating disorder | D056912 | — | F50.2 | — | 1 | — | — | — | 1 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
Magnetic resonance imaging | D008279 | — | — | — | — | — | — | 1 | 1 |
Electroconvulsive therapy | D004565 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Vortioxetine |
INN | vortioxetine |
Description | Vortioxetine is an N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. It has a role as an antidepressant, an anxiolytic drug, a serotonergic agonist and a serotonergic antagonist. It is a N-arylpiperazine and an aryl sulfide. It is a conjugate base of a vortioxetine(1+). |
Classification | Small molecule |
Drug class | antidepressants (fluoxetine type): thioether derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1 |
PDB | — |
CAS-ID | 508233-74-7 |
RxCUI | — |
ChEMBL ID | CHEMBL2104993 |
ChEBI ID | 76016 |
PubChem CID | 9966051 |
DrugBank | DB09068 |
UNII ID | 3O2K1S3WQV (ChemIDplus, GSRS) |